Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) stock was trading low in the after-hours as they dropped -13.06% to $4.46. Over the past three months, the stock’s price change was -21.08% and -1.91% over the five days. It is currently trading at a low of $53.15 and touched a high of $138.79 in the past 12 months.
So, what are they good at…?
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Infusion solutions that improve the quality of life for millions of patients worldwide are developed, manufactured, and commercialized by KORU Medical Systems (NASDAQ: KRMD).
On January 25, 2021, the company reported preliminary financial results for the whole fiscal year ended December 31, 2020. Additionally, Jim Beck was named Interim Chief Executive Officer of the Company, effective immediately after serving as a KORU Medical Board member. Don Pettigrew has resigned from his position as President and CEO, and the Board of Directors has engaged a leading executive search firm to assist in hiring a new CEO.
For the full year 2020, preliminary revenue is expected to be $24.0 million, an increase of 3.4% from $23.2 million in 2019.
Preliminary cash, cash equivalents, marketable securities, and other pro forma financial assets are projected to amount to $27.3 million at the end of 2020, compared to $5.9 million at the end of 2019.
Meanwhile, the Company noted several factors that impacted preliminary 2020 results, including the significant demand fluctuations resulting from large-scale inventory purchasing. Growth in net revenue was slower due to strengthening the Company’s purchasing power with large customers. International sales and clinical trial partnerships performed less than expected in the second half of 2020. State and local guidelines prevented many people from seeking care from their healthcare professionals in 2020, resulting in a slowdown in new patient starts.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can gather important information from reading the tea leaves about who is buying and selling.65.79% of this stock is owned by institutions, while insiders hold 4.40%. The top institutional shareholder is Horton Capital Management, LLC with 29.66%, followed by First Light Asset Management, LLC with 18.19%.